Decursinol angelate Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

328.36

DMSO: 65mg/mL (197.95mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C19H20O5

CC1(C)Oc2cc(OC(C=C3)=O)c3cc2C[C@@H]1OC(/C(/C)=C\C)=O

130848-06-5

VEGFR
JNK
ERK

Here, we show that treatment with these compounds improves wound healing by HaCaT human keratinocytes. Wound healing was increased by treatment with up to a threshold concentration of decursin, Decursinol angelate, a mixture of both, and a nano-emulsion of these compounds, but inhibited by treatment with higher concentrations. Immunoblotting and fluorescence imaging of cells expressing an epidermal growth factor receptor (EGFR) biosensor demonstrated that these compounds did not stimulate wound healing by inducing EGFR phosphorylation. Rather, transcriptional analysis revealed that decursin and Decursinol angelate improved wound healing by upregulating the expression of genes encoding extracellular matrix remodeling proteins, inflammatory cytokines, and growth factors.

Angiogenesis; VEGFR; MAPK